Stifel Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Maintains Target Price $42

robot
Abstract generation in progress

Stifel has reiterated its Buy rating on KalVista Pharmaceuticals (KALV.US) and maintained its target price of $42. This indicates a continued positive outlook from the analyst firm regarding the company’s stock performance.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin